Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Total Current Liabilities (2022 - 2025)

Historic Total Current Liabilities for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to $29.1 million.

  • Centessa Pharmaceuticals' Total Current Liabilities rose 1028.55% to $29.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.1 million, marking a year-over-year increase of 1028.55%. This contributed to the annual value of $58.0 million for FY2024, which is 4725.91% up from last year.
  • Per Centessa Pharmaceuticals' latest filing, its Total Current Liabilities stood at $29.1 million for Q3 2025, which was up 1028.55% from $29.7 million recorded in Q2 2025.
  • In the past 5 years, Centessa Pharmaceuticals' Total Current Liabilities ranged from a high of $58.0 million in Q4 2024 and a low of $24.2 million during Q1 2025
  • Moreover, its 4-year median value for Total Current Liabilities was $29.7 million (2025), whereas its average is $33.1 million.
  • Within the past 5 years, the most significant YoY rise in Centessa Pharmaceuticals' Total Current Liabilities was 4725.91% (2024), while the steepest drop was 2445.5% (2024).
  • Over the past 4 years, Centessa Pharmaceuticals' Total Current Liabilities (Quarter) stood at $38.3 million in 2022, then grew by 2.73% to $39.4 million in 2023, then surged by 47.26% to $58.0 million in 2024, then crashed by 49.79% to $29.1 million in 2025.
  • Its Total Current Liabilities was $29.1 million in Q3 2025, compared to $29.7 million in Q2 2025 and $24.2 million in Q1 2025.